Low-efficacy HIV vaccines: Potential for community-based intervention programmes

Lancet

Volumn 348, Issue 9033, 1996, Pages 1010-1013

  Anderson, R M ^a   Garnett, G P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ARTICLE; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION; MATHEMATICAL MODEL; PRIORITY JOURNAL; PUBLIC HEALTH;

EID: 0030581592     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07100-0     Document Type: Review

References (19)

1. 1 Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV specific cytotoxic T-cells in HIV exposed but uninfected Gambian women. Nat Med 1995; 1: 59-64.
2. 2 Grosskurth H, Mosha F, Todd J, et al. Impact of improved treatment of sexually transmitted disease on HIV infection in rural Tanzania: randomised controlled trial. Lancet 1995; 346: 530-36.
3. 3 Bloom BR. A perspective on AIDS vaccines. Science 1996; 272: 1888-90.
4. 4 Moore J, Anderson R. The WHO and why of HIV vaccine trials. Nature 1994; 372: 313-14.
5. 5 Anderson RM, Gupta S, May RM. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature 1991; 350: 356-59.
6. 6 Blower SM, McLean AR. Prophylactic vaccines, risk behavior change and the probability of eradicating HIV in San Francisco. Science 1994; 265: 1451-54.
7. 7 Anderson RM, Swinton J, Garnett GP. Potential impact of low efficacy HIV-1 vaccines in populations with high rates of infection. Proc R Soc Lond B 1995; 261: 147-51.
8. 8 Halloran ME, Haber M, Longini LM, Struchiner CJ. Direct and indirect effects in vaccine efficacy and effectiveness. Epidemiology 1991; 133: 323-34.
9. 9 Halloran ME, Longini IM, Haber MJ, Struchiner CJ, Brunet RC. Exposure efficacy and change in contact rates in evaluating prophylatic HIV vaccines in the field. Stat Med 1994; 13: 357-77.
10. 10 Rida WN, Lawrence DN. Some statistical issues in HIV vaccine trials. Stat Med 1994; 13: 19-20.
11. 11 McLean AR, Blower SM. Imperfect vaccines and herd immunity to HIV. Proc R Soc Lond B 1993; 253: 9-13.
12. 12 Anderson RM, May RM. Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press, 1991.
13. 13 Garnett GP, Anderson RM. Factors controlling the spread of HIV in heterosexual communities in developing countries: patterns of mixing between different age and sexual activity classes. Phil Trans R Soc Lond B 1993; 342: 137-59.
14. 14 Parker G, Anderson RM. Concurrent sexual partnerships: mathematical models of the transmission dynamics of the HIV and the case reproductive number. IM AJ Math Appl Med Biol (in press).
15. 15 Garnett GP, Anderson RM. Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations. IM AJ Math Appl Med Biol 1994; 11: 161-92.
16. 16 Gregson S, Garnett GP, Shakespeare R, Foster G, Anderson RM. Determinants of the demographic impact of HIV-1 in sub-Saharan Africa: the effect of a shorter mean adult incubation period on trends in orphanhood. Health Transition Rev 1994; 4: 65-92.
17. 17 Mulder D, Nunn A, Kamali A, Kegeya-Kayondo J. Decreasing HIV-1 seroprevalence in young adults in a rural Ugandan cohort. BMJ 1995; 311: 333-36.
18. 18 Garnett GP, Anderson RM. Strategies for limiting the spread of HIV in developing countries: conclusions based on studies of the transmission dynamics of the virus. J AIDS 1995; 9: 500-13.
19. 19 Jackson DJ, Martin HL, Burayo JJ, et al. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya. AIDS 1995; 9: 1279-83.